Search

Copyright of Chinese Journal of Osteoporosis is the property of Chinese Journal of Osteoporosis and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Osteoporosis is the property of Chinese Journal of Osteoporosis and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective　To study the therapeutic value of 99Tc－MDP for bone repairing in aseptic necrosis of the femoral head （ANFH）．Methods　The animal experiment included ２ stages： the establishment of animal model and the treatment observation． ANFH animal model was made by dexamethasone intramuscular injection．Intramuscular injection of dexamethasone was used to establish the ANFH model．In the first stage of ８ weeks， normal group （Group A） and ANFH model group （Group B） were set up．The successful animal model was proved by cell pathology， bone morphology， BMD， tetracycline double labeling， bone scintigraphy ROI value， X－ray， and CT．In the second stage of １６ weeks， normal control group （Group C）， ANFH model control Group （Group D），99Tc－MDP therapy Group (Group E), and alendronate sodium therapy group （Group F） were set up．The same tests were applied like in stage １ and the efficacy in Group E and Group F was valued．SPSS１３ was used for statistical analysis． Results　At the end of stage １， the pathology showed that no bone tissue was destroyed in Group A， but in Group B the surface soft tissue of the femoral head was destroyed， and bone trabecular breaking and bone lacuna increased．BMD， bone histomorphology， tetracycline double labeling decreased and bone scintigraphy ROI， serum BALP and BGP increased in Group B． ANFH could be seen by X ray and CT in Group B．After １６－week therapy in Group E and Group F， all the test results showed a nearly same results between Group A， C and Group B， D．Improved result showed in Group E and Group F， especially in Group E for bone repairing， bone trabecular increasing， and bone lacuna disappearing．All the results were comparable between Group E and Group C．Conclusion　Animal study shows an apparent result of 99Tc－MDP treatment for ANFH. 99Tc－MDP not only has the same function like alendronate sodium showing increased bone trabeculae in tetracycline double labeling test， but also reveals the potential function in promoting osteoblast function and bone tissue repairing indicated by bone lacuna disappearing． [ABSTRACT FROM AUTHOR]

Objective To investigate the value of 99Tc-MDP therapy in aseptic necrosis femur head (ANFH). Methods The animal experiment was divided into 2 stages: animal model establishment and clinical observation. In the first stage, Group A (normal group) and Group B(ANFH group) were set up. The animal ANFH model was established by intravenous injection of dexamethasone sodium phosphate for 8 weeks. Bone pathology, histomorphology, bone mineral density, tetracycline double labeling experiment, radionuclide bone scintigraphy ROI ratio value, X-ray, and CT were examined. The second stage of the experiment started until the ANFH model had been proved. During the second stage, these groups were set up for the further 16 week-therapy based on the ANFH animal model: Group C (normal control), Group D(ANFH control), Group E(99Tc-MDP therapy), and Group F(alendronate therapy). After the treatment, the efficacy in Group E and Group F was valued. A SPPSS13. 0 softw are was used for statistical analysis. Results After 2 stages of ANFH model establishment and clinical observation, the results, including bone pathology, histomorphology, bone mineral density, tetracycline double labeling experiment, and ROI ratio of radionuclide bone scintigraphy, show ed apparent difference between Group A and B(p < 0. 01), indicating the success of animal modeling. After the treatment, the bone pathology in Group E show ed that trabecular bone in the femoral head lined regularly with a little scatter. But the repair was apparent comparing with that in Group D. In Group F trabecular bone in the femoral head show ed scattered and irregular lining and little broken. Comparing with that in Group D, the situation improved in Group F. The results of bone mineral density, tetracycline double labeling experiment, and ROI ratio of radionuclide bone scintigraphy also supported the improvement(p < 0. 05). Conclusion On the bases of ANFH animal model, 99Tc-MDP and Alendronate have got different therapy value and99Tc-MDP show ed an apparent remoulding result. 99Tc-MDP can reach the ANFH target tissue. Besides controlling bone absorption, it also can maintain the activity of superoxide dismutase(SOD), protect the bone tissue absorption from free radius and prevent from its further damaging. From the tetracycline double labeling experiment we can conclude that the increased deposition rate maybe relate to the bone cell proliferation. [ABSTRACT FROM AUTHOR]